Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Liqin Ping"'
Autor:
Yan Gao, Haixia He, Xueping Li, Liling Zhang, Wei Xu, Ru Feng, Wenyu Li, Yin Xiao, Xinxiu Liu, Yu Chen, Xiaoxiao Wang, Bing Bai, Huijing Wu, Qingqing Cai, Zhiming Li, Jibin Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jiaying Mao, Xiujin Chen, Baitian Zhao, Huiqiang Huang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and the duration of response (DOR) need to be improved. This phase 1b/2
Externí odkaz:
https://doaj.org/article/583932d69bc54c3c805fc537107b6589
Autor:
Yan Gao, Liqin Ping, Xiaoxiao Wang, Bing Bai, Xuanye Zhang, Qingqing Cai, Zhi-Ming LI, Huang He, Liang Yang, Yizhuo Zhang, Huiqiang Huang
Publikováno v:
HemaSphere, Vol 7, p e31674b9 (2023)
Externí odkaz:
https://doaj.org/article/9ddaaf6fe90e4ccb977299ff06812b58
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Background: Pyroptosis, a kind of programmed cell death characterized by the rupture of cell membranes and the release of inflammatory substances, plays an important role in the occurrence and development of cancer. However, few studies focus on the
Externí odkaz:
https://doaj.org/article/4808eb37dc2e4dec8c553bf6d6c09e68
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Background: Ferroptosis, a regulated cell death which is driven by the iron-dependent peroxidation of lipids, plays an important role in cancer. However, studies about ferroptosis-related Long non-coding RNAs (lncRNAs) in breast cancer (BC) are limit
Externí odkaz:
https://doaj.org/article/a78d858abdf94e6d9f475cc12c6c4f09
Autor:
Yujia Zhong, Jianlan Xie, Jierong Chen, Liqin Ping, Shengbing Zang, Yingchun Zhang, Yanfen Feng, Yuhua Huang
Publikováno v:
American Journal of Surgical Pathology; Feb2024, Vol. 48 Issue 2, p174-182, 9p
Autor:
He Yanxia, Yan Gao, Liqin ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhi-Ming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan liu, Huiqiang Huang
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:2017-2027
Purpose Anti-PD-1 antibody (anti-PD-1 mAb) showed favourable outcomes in some patients with relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL). However, the role of anti-PD-1 antibody in NK/T-cell lymphoma-associated hemophagocytic lymph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdbfe97ac6258cef91cbb51a03203308
https://doi.org/10.1007/s00432-022-04147-2
https://doi.org/10.1007/s00432-022-04147-2
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 11; Pages: 1840
Background: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent type of lymphoma that is potentially curable by chemotherapy. Immunogenic cell death (ICD) is regarded as an essential process for the clearance of residual tumor cells. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a40feb0ac1a2642add2715e778962008
https://pubmed.ncbi.nlm.nih.gov/36579538
https://pubmed.ncbi.nlm.nih.gov/36579538
Autor:
Gao Yan, Cheng Huang, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yanxia He, Liqin Ping, Huiqiang Huang
Publikováno v:
Blood. 140:9393-9394
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f08dcda268b2114e1358dd1fc3f7b04e
https://doi.org/10.1182/blood-2022-165874
https://doi.org/10.1182/blood-2022-165874
Autor:
Gao Yan, Xiaoxiao Wang, Bing Bai, Xue-Ping Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Publikováno v:
Blood. 140:3737-3738
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d13bf0e7fcfbe06986c7e7f8c0daf49
https://doi.org/10.1182/blood-2022-166936
https://doi.org/10.1182/blood-2022-166936
Publikováno v:
Oxidative Medicine and Cellular Longevity.
Background. T lymphoblastic lymphoma/leukemia (T-LBL/ALL) is an aggressive malignant tumor with 5-year overall survival (OS) rate reached 80% after high-dose chemotherapy. Due to the relatively low incidence of T-LBL/ALL, only a few risk factors have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3e3d3b56a1f4bdc45bc1f745d9e8ad